| Breathing training(n = 94 if not stated) | Control(n = 89 if not stated) | |
| Age (years)* | 46.0 (33.0–57.3) | 46.0 (35.0–57.0) |
| Female | 52 (58.4%) | 60 (63.8%) |
| AQLQ score† | 4.2 (0.9) | 4.3 (1.0) |
| Body mass index* | 27.7 (24.0–31.3) | 25.7 (23.0–29.2) |
| ACQ score† | 1.4 (0.8) | 1.5 (0.9) |
| NQ score† | 24.1 (9.4) | 23.2 (8.4) |
| % Predicted FEV1† | 87.3 (18.8) | 91.8 (21.6) |
| Bronchodilator reversibility (%)* | 5.5 (2.2–10.2), n = 74 | 5.7 (3.5–12.2), n = 77 |
| ICS dose (μg/day BDP equivalent)* | 400 (0–525) | 400 (113–600) |
| LABA treatment | 43 (46.3%) | 36 (40.4%) |
| LTRA treatment | 3 (3.2%) | 2 (2.3%) |
| Oral steroid burst in previous year | 29 (30.5%) | 19 (21.3%) |
| Average daily SABA use (doses/day)† | 1.39 (1.28) | 1.47 (1.42) |
| BTS treatment step | ||
| Step 1 | 20 (21.3%) | 20 (22.5%) |
| Step 2 | 37 (39.4%) | 34 (38.2%) |
| Step 3 | 35 (37.2%) | 34 (38.2%) |
| Step 4 | 2 (2.1%) | 1 (1.1%) |
| Rhinitis/hay fever | 58 (61.1%) | 55 (61.8%) |
| HAD anxiety score† | 7.2 (3.8) | 7.5 (4.0), n = 88 |
| HAD depression score† | 3.3 (3.0) | 3.6 (2.9), n = 88 |
*Median (interquartile range). †Mean (SD).
ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; BDP, beclomethasone dipropionate; BTS, British Thoracic Society; FEV1, forced expiratory volume in 1 s; HAD, Hospital Anxiety and Depression Questionnaire; ICS, inhaled corticosteroids; LABA, long-acting β1 agonist; LTRA, leukotriene receptor antagonist; NQ, Nijmegen Questionnaire; SABA, short-acting β1 agonist.